Prenetics Global Limited announced that CEO Danny Yeung and CFO Brian Rosin purchased $1.0 million of the company's ordinary shares on the open market between August 20 and 25, 2026. This transaction brings their cumulative personal investment since November 2025 to approximately $3.75 million, with no shares sold during this period. The purchases occurred within an open trading window following the release of second quarter 2026 financial results, which reported total revenue of $46.5 million and raised full year 2026 guidance to $220–$230 million. Prenetics Global Limited is a consumer health company focused on advancing human health and longevity through its AI-native direct-to-consumer wellness brand IM8.

Prenetics Global Limited announced a multi-year global partnership with actress Lily Collins as the first IM8 Global Ambassador from film and television, granting her equity ownership in the company. The filing also details significant financial updates: Prenetics raised its full-year 2026 revenue guidance to $220–$230 million and initiated FY 2027 guidance of $400+ million. IM8 reported shipping approximately 200,000 servings daily across 46 countries, with 54% of revenue generated outside the United States. The company achieved positive consolidated Adjusted Free Cash Flow in July 2026 and expects to remain cash flow positive through Q3 2026 and beyond. Prenetics Global Limited operates as a consumer health and longevity company, primarily known for its premium supplement brand IM8.

Prenetics Global Limited has closed a $1 billion growth financing arrangement with General Catalyst's Customer Value Fund for its IM8 business unit. This transaction provides significant capital for growth in its healthcare-related technology segment. Prenetics Global Limited operates in the healthcare technology sector through its various business units.